Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...
Related Questions
How will the lack of dose‑limiting toxicities and the higher 30x dose in the fourth cohort influence the likelihood and timeline of regulatory approval for Anixa’s ovarian cancer CAR‑T therapy?
What immediate impact could this trial update have on ANIX’s stock price and trading volume, considering market expectations and analyst sentiment?
How does Anixa’s CAR‑T progress compare to competing ovarian cancer immunotherapies, and what market share potential does it create if the trial continues to succeed?